This case report documents that highly active antiretroviral therapy (HAART) can lead to the regression of Kaposi's sarcoma (KS) lesions in the auditory canal of an HIV-infected male from Chennai, India. In resource-limited settings where administering anti-KS chemotherapeutic agents may not be feasible, HAART alone can be an option in HIV-infected individuals with KS.
MocroftA, KirkO, ClumeckN, The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: The EuroSIDA Study. Cancer2004;100:2644–54
2.
BrodtH, KampsBS, GuteP, KnuppB, StaszewskiS, HelmEB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS1997;11:1731–8
3.
DupontC, VasseuraE, BeauchetA, Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS2000;14:987–93
4.
CattelanA, CalabroML, GasperiniP, Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr2001;28:44–9
5.
MartinezV, CaumesE, GambottiL, Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer2006;94:1000–6
6.
ShroffH, DashatwarDR, DeshpandeRP, WaigmannHR. AIDS-associated Kaposi's sarcoma in an Indian female. J Assoc Ind Phys1993;41:241–2
7.
KumarasamyN, SolomonS, YesudianP, SugumarP. First report of kaposi's sarcoma in an AIDS patient from Madras, India. Ind J Dermatol1996;41:23–5
8.
KumarasamyN, SolomonS, ChaguturuSK, The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis2005;41:1525–8
9.
BundowD, AboulafiaDM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol2004;27:81–4
10.
MurdacaG, CampelliA, SettiM, IndiveriF, PuppoF. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS2002;16:304–5
